Saudi pharmacy and healthcare retailer Nahdi Medical (4164) reported a 6.6% year-on-year rise in third-quarter 2026 net profit to SAR 171.8 million from SAR 161.2 million as higher sales supported overall earnings.
Sales growth offsets margin pressure
Higher sales lifted gross and operating profit, although the gross margin came under pressure from a changing business mix and investment in healthcare services and e-commerce channels.
What investors will watch
Investors will focus on the profitability of the core pharmacy business, returns from healthcare and digital expansion, inventory efficiency and operating costs. Net profit growth is encouraging, but the margin trajectory remains central to assessing whether the improvement can be sustained.
اكتشاف المزيد من Market News | أخبار الأسواق
اشترك للحصول على أحدث التدوينات المرسلة إلى بريدك الإلكتروني.